COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,440 Articles (22,835 medRxiv, 8,605 bioRxiv)

Most recent first Previous |  Page 860: Articles 8591-8600  | Next

Glasses and risk of COVID-19 transmission - analysis of the Virus Watch Community Cohort study.
Navaratnam, A. M. D., O'Callaghan, C., Beale, S., Nguyen, V., Aryee, A., Braithwaite, I., Byrne, T. E., Fong, W. L. E., Fragaszy, E., Geismar, C., Hoskins, S., Kovar, J., Patel, P., Shrotri, M., Weber, S., Yavlinsky, A., Aldridge, R. W., Hayward, A. C.
10.1101/2022.03.29.22272997 — Posted: 2022-04-04
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is mediated by a stereotyped clonotypic antibody
Wang, J. J., Armour, B., Chataway, T., Troelnikov, A., Colella, A., Yacoub, O., Hockley, S., Tan, C. W., Gordon, T. P.
10.1101/2022.03.28.22272975 — Posted: 2022-04-04
Biochemical, Biophysical, and Immunological Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections
Kratochvil, M. J., Kaber, G., Demirdjian, S., Cai, P. C., Burgener, E. B., Nagy, N., Barlow, G. L., Popescu, M., Nicolls, M. R., Ozawa, M. G., Regula, D. P., Pacheco-Navarro, A. E., Yang, S., de Jesus Perez, V., Karmouty-Quintana, H., Peters, A. M., Zhao, B., Buja, M. L., Johnson, P. Y., Vernon, R. B., Wight, T. N., Stanford COVID-19 Biobank Study Group, , Rogers, A. J., Spakowitz, A. J., Milla, C. E., Heilshorn, S. C., Bollyky, P. L.
10.1101/2022.03.28.22272848 — Posted: 2022-04-04
The trustworthiness and impact of trial preprints for COVID-19 decision-making: A methodological study
Zeraatkar, D., Pitre, T., Leung, G., Cusano, E., Argawal, A., Khalid, F., Escamilla, Z., Cooper, M., Ghadimi, M., Wang, Y., Verdugo, F., Rada, G., Kum, E., Qasim, A., Bartoszko, J. J., Siemieniuk, R., Patel, C. J., Guyatt, G., Brignardello-Petersen, R.
10.1101/2022.04.04.22273372 — Posted: 2022-04-04
Significant impacts of the COVID-19 pandemic on race/ethnic differences in USA mortality
Aburto, J. M., Tilstra, A. M., Floridi, G., Dowd, J. B.
10.1101/2022.04.04.22273385 — Posted: 2022-04-04
A simple algorithm based on initial Ct values predicts the duration to SARS-CoV-2 negativity and allows more efficient test-to-release and return-to-work schedules
Anastasiou, O. E., Le-Trilling, V. T. K., Trilling, M.
10.1101/2022.04.04.22273384 — Posted: 2022-04-04
Clinical Variables Correlate with Serum Neutralizing Antibody Titers after COVID-19 mRNA Vaccination in an Adult, US-based Population
Zhao, M., Slotkin, R., Sheth, A. H., Pischel, L., Kyriakides, T., Sutton, R. E., Gupta, S.
10.1101/2022.04.03.22273355 — Posted: 2022-04-04
Estimating the number of breakthrough COVID-19 deaths in the United States
Smith, J. P.
10.1101/2022.04.04.22272731 — Posted: 2022-04-04
Cardiac impairment in Long Covid 1-year post-SARS-CoV-2 infection
Roca-Fernandez, A., Wamil, M., Telford, A., Carapella, V., Borlotti, A., Monteiro, D., Thomaides-Brears, H., Kelly, M. D., Dennis, A., Banerjee, R., Robson, M., Brady, M., Lip, G., Bull, S., Heightman, M. J., Ntusi, N., Banerjee, A.
10.1101/2022.04.03.22272610 — Posted: 2022-04-04
Variation in National COVID-19 Mortality Rates Across Asian Subgroups in the United States, 2020
Xu, J. J.
10.1101/2022.04.02.22273341 — Posted: 2022-04-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).